Immuno-Oncology | Specialty

Dr. Gandara on Treatment Options for Squamous Cell NSCLC

August 20th 2018

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, 2017 Giant of Cancer Care in Lung Cancer, discusses treatment options for patients with squamous cell non–small cell lung cancer.

FDA Grants Full Approval to Pembrolizumab Plus Chemo for NSCLC

August 20th 2018

The FDA has granted a full approval to frontline pembrolizumab for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer.

Neoadjuvant Immunotherapy Emerges as a New Frontier

August 20th 2018

Although checkpoint blocking immunotherapy has significantly improved outcomes for patients with advanced and metastatic disease, researchers believe the modality also may be effective in the neoadjuvant setting.

FDA Approves Nivolumab for Small Cell Lung Cancer

August 17th 2018

The FDA has approved single-agent nivolumab for the treatment of patients with small cell lung cancer with disease progression following 2 or more lines of therapy.

Dr. Papadimitrakopoulou on Importance of More Targeted Therapies in NSCLC

August 16th 2018

Vassiliki Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the need for more targeted therapies in non–small cell lung cancer.

Dr. Bunn on TMB as a Biomarker in Small Cell Lung Cancer

August 15th 2018

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses tumor mutational burden as a biomarker in small cell lung cancer.

Expert Explains Work Needed for Immunotherapy/RT Approaches in NSCLC

August 15th 2018

James Larner, MD, discusses the process by which radiation interacts with the immune system and how physicians are working to improve treatment responses for patients with non–small cell lung cancer.

Immunotherapy Data Lead Lung Cancer Landscape Following ASCO 2018

August 15th 2018

Apar Kishor Ganti, MD, discusses some of the most intriguing abstracts in lung cancer recently presented at medical meetings.

Dr. Youngblood on T-Cell Differentiation/Exhaustion in Pediatric Cancer

August 13th 2018

Benjamin A. Youngblood, PhD, assistant member, Department of Immunology, St. Jude Children’s Research Hospital, discusses the impact of T-cell differentiation and exhaustion in pediatric cancer.

Dr. Makker on Synergy Between Lenvatinib and Pembrolizumab in Endometrial Cancer

August 10th 2018

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the synergy between lenvatinib and pembrolizumab in the treatment of patients with endometrial cancer.

Dr. Camidge on Biomarker Combinations in NSCLC

August 10th 2018

David Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses biomarker combinations in non–small cell lung cancer (NSCLC).

Dr. Herbst on Key Immunotherapy Findings in NSCLC

August 10th 2018

Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses key immunotherapy findings in non–small cell lung cancer, presented at the 2018 ASCO Annual Meeting.

Dr. Menter on Neoadjuvant Immunotherapy in Early-Stage NSCLC

August 10th 2018

Alexander R. Menter, MD, oncologist, Kaiser Permanente, discusses the use of neoadjuvant immunotherapy in patients with early-stage non–small cell lung cancer (NSCLC).

Dr. Gupta on Genomic Characterization of MIBC Histology to Predict Response

August 9th 2018

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses genomic characterization of muscle invasive bladder cancer histology to predict therapy response.

Enfortumab Vedotin Emerging as Post-Immunotherapy Option in Bladder Cancer

August 9th 2018

Jonathan E. Rosenberg, MD, discusses the promise of enfortumab vedotin in patients with bladder cancer who previously received a checkpoint inhibitor, and reflects on the rapid pace of change in the urothelial cancer landscape.

Sznol Reflects on Immunotherapy Advances in mRCC

August 9th 2018

Mario Sznol, MD, discusses the latest developments with immunotherapy in metastatic renal cell carcinoma.

Dr. Bota on Marizomib in Patients with Glioma

August 8th 2018

Daniela Bota, MD, PhD, medical director, Neuro-Oncology Program, associate professor, Neurology School of Medicine, UC Irvine Health, discusses marizomib for the treatment of patients with glioma.

Expert Highlights Role of TMB in Evolving Immuno-Oncology Landscape

August 8th 2018

Conor E. Steuer, MD, shares insight on the emerging role of tumor mutational burden in relation to immunotherapy for patients with cancer.

Borghaei Discusses Nivolumab/Ipilimumab CheckMate-227 NSCLC Findings

August 6th 2018

Hossein Borghaei, DO, MS, discusses the results of the subgroup analysis of the ongoing CheckMate-227 trial in metastatic non–small cell lung cancer.

Dr. Galsky on Neoadjuvant Immune Checkpoint Blockade in Bladder Cancer

August 3rd 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses neoadjuvant immune checkpoint inhibition in patients with bladder cancer.